All In Biotech

Drug Trial Radar · NCT07640295

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

A Multicenter, Phase Ib/III Study to Evaluate JAB-23E73 in Combination With Nab-Paclitaxel and Gemcitabine in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Harboring KRAS Gene Alterations

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 16, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • JAB-23E73 tablet,nab-paclitaxel,gemcitabineDrug

    Orally, intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLT)Time frame: Up to 28 days
  2. Adverse events.safety evaluationTime frame: Up to approximately 3 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Not yet recruiting

  • Shanghai Jiaotong University School of Medicine Ruijin Hospital

    Shanghai, China · Recruiting

  • ShanXi Cancer Hospital

    Taiyuan, China · Recruiting

  • Hubei Province Hospital

    Wuhan, China · Not yet recruiting

  • Wuhan Union Hospital Of China

    Wuhan, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Not yet recruiting

  • The First Affiliated hospital of Zhengzhou University

    Zhengzhou, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.